Dr. Meyers is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
3181 Sw Sam Jackson Park Rd
Portland, OR 97239Phone+1 503-494-5058
Education & Training
University of Utah HealthFellowship, Hematology and Medical Oncology, 2001 - 2004
Oregon Health & Science University (OHSU Health)Residency, Internal Medicine, 1998 - 2001
University of Chicago Division of the Biological Sciences The Pritzker School of MedicineClass of 1998
Certifications & Licensure
OR State Medical License 1999 - 2025
WA State Medical License 2022 - 2025
UT State Medical License 2001 - 2006- American Board of Internal Medicine Internal Medicine
- American Board of Internal Medicine Geriatric Medicine
- American Board of Internal Medicine Hematology
- American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Clinical Trials
- Fludarabine-based Conditioning for Severe Aplastic Anemia (BMT CTN 0301) Start of enrollment: 2006 Jan 01
- Chronic Graft-versus-Host Disease Treatment (BMT CTN 0801) Start of enrollment: 2010 Apr 01
- Reduced Intensity Regimen vs Myeloablative Regimen for Myeloid Leukemia or Myelodysplastic Syndrome (BMT CTN 0901) Start of enrollment: 2011 Jun 01
- Join now to see all
Publications & Presentations
PubMed
- 30 citationsComparison and validation of the 2022 European LeukemiaNet guidelines in acute myeloid leukemia.Curtis A Lachowiez, Nicola Long, Jennifer Saultz, Arpita Gandhi, Laura F Newell
Blood Advances. 2023-05-09 - 14 citationsEngrafted Donor-Derived Clonal Hematopoiesis after Allogenic Hematopoietic Cell Transplantation is Associated with Chronic Graft-versus-Host Disease Requiring Immunosu...Laura F. Newell, Todd Williams, James K. Liu, Yun Yu, Yiyi Chen
Transplantation and Cellular Therapy. 2021-08-01 - 63 citationsA phase 1 trial of itacitinib, a selective JAK1 inhibitor, in patients with acute graft-versus-host diseaseMark A. Schroeder, H. Jean Khoury, Madan Jagasia, Haris Ali, Gary J. Schiller
Blood Advances. 2020-04-28
Abstracts/Posters
- Equate, a Phase 1b/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of a Novel Targeted Anti-CD6 Therapy, Itolizu...Gabrielle Meyers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Retrospect Reviews of PNH Tests with Long-Term Follow-up in a Single InstitutionGabrielle Meyers, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
Press Mentions
Monkey Model Offers Clues for Potential Widespread HIV Cure in PeopleMay 25th, 2023- Research Offers Clues for Potential Widespread HIV Cure in People: New Study Reveals First Details on How Stem Cell Transplantation Can Kill Virus That Causes AIDSMay 25th, 2023
- New Study Reveals First Details on How Stem Cell Transplant Can Kill Viruses That Cause AIDS – ScienceDailyJune 3rd, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
